Clinical trials
Fatty Liver Disease clinical trials
Below are recruiting fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 176 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03875625Recruiting
Tracking body fat and liver fat after weight-loss treatment
This study looks at how body fat and liver fat change after bariatric (weight-loss) surgery or a lifestyle program. You may join if you have overweight or obesity and can safely have MRI scans, so researchers can compare results between treatment approaches.
Hong Kong, ShatinAges 18–65 - NCT04365855Recruiting
Study of fatty liver risk in local adults
This study looks at how common fatty liver disease is and what factors may be linked to it in adults in Olmsted County. You may be asked about health history, alcohol use, and possibly to undergo MRI scans.
Rochester, MinnesotaAges 18 years+ - NCT06704321Recruiting
Effects of TOTUM-448 on liver fat and heart health
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
Québec, QuebecAges 18–75 - NCT00575133Recruiting
Study of people with fatty liver disease
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
Zurich, Canton of ZurichAges 18 years+ - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05546086Recruiting
Beijing health study for adults who live in Beijing
This study collects health information from adults (18+) who are permanent residents of Beijing. It aims to learn patterns about health in the local population and how different factors may affect outcomes over time.
BeijingAges 18 years+ - NCT05597709Recruiting
Study diabetes patients to measure MAFLD in Jiangsu
This study checks how common a condition called MAFLD is among people with type 2 diabetes in Jiangsu, China. It may help doctors understand how often this liver-related problem occurs and guide future care for people with type 2 diabetes.
Nanjing, JiangsuAges 18 years+ - NCT05625750Recruiting
Study of people diagnosed with fatty liver from not-too-much alcohol
This is an observational study for people diagnosed with nonalcoholic fatty liver disease (fatty buildup in the liver not mainly caused by heavy drinking). It may help researchers better understand this condition, especially how it shows up on tests and how people report relevant health information.
Changsha, HunanAges 18–75 - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT05046483Recruiting
Blood sugar study after a new heart attack
This study measures how your body handles sugar and related hormones in people after a new STEMI heart attack, and compares them with people who do not have diabetes or have prediabetes. The goal is to better understand metabolic changes after the event, which could help future care.
Düsseldorf, North Rhine-WestphaliaAges 18–80 - NCT06061042Recruiting
Time-restricted eating for metabolic health
This study tests whether eating only during a specific time window each day can improve metabolic health in people with obesity and insulin resistance. If you have a high BMI and early signs of diabetes, this trial might help you understand a simple dietary change.
Amsterdam, North HollandAges 50–75 - NCT06115876Recruiting
Kuwait diabetes long-term follow-up study
This study checks in on people with prediabetes or type 2 diabetes who were part of an earlier Kuwait diabetes study. It aims to understand how their condition has changed and what health care they may need.
Kuwait CityAges 21–75 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT07726368RecruitingPhase 1
Study of ECC4703 with sulfasalazine and pitavastatin
This early-phase study tests how a new drug (ECC4703) works in the body when taken with two other common medications (sulfasalazine and pitavastatin). Healthy volunteers are needed to help researchers understand potential drug interactions and safety.
Melbourne, VictoriaAges 18–65 - NCT06649162Recruiting
Fatty liver risk in type 2 diabetes and new combo therapy
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
Andong, Gyeongsangbuk-doAges 19 years+ - NCT05480696RecruitingPhase 2
Soluble fiber supplement for fatty liver in kids
This Phase 2 study tests whether a soluble fiber supplement can improve fatty liver disease in children who have obesity and confirmed NAFLD. It may help reduce liver fat and related liver enzyme elevations measured during clinic visits and MRI.
Hamilton, OntarioAges 8–17 - NCT06585982Recruiting
Synbiotics for MAFLD: gut health and liver fat study
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
Semarang, SemarangAges 25–55 - NCT07632677Recruiting
Testing a liver inflammation score in diabetes and fatty liver
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
Bengbu, AnhuiAges 18 years+ - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT07493967Enrolling by invitation
Stomach balloon for fatty liver disease study
This study looks at how a stomach balloon affects symptoms and quality of life in people with obesity and fatty liver disease. It will track your health over time to see if the balloon helps.
Dallas, TexasAges 18 years+ - NCT06694935RecruitingPhase 1
Testing QX1206 in type 2 diabetes with fatty liver
This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.
TorontoAges 18–64 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07376486Recruiting
Early treatment for type 2 diabetes using a new duodenal procedure
This study tests a new procedure called pulsENDO, which is done in the first part of the small intestine (the duodenum) to help treat type 2 diabetes. It may be an option for people who were recently diagnosed and have good blood sugar control with little or no diabetes medication.
ShatinAges 18–60
Hear when a new Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fatty liver disease?
- Yes. Clin2 currently lists 176 recruiting fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.